OBAGI MEDICAL PRODS (NASDAQ:OMPI)
10.76
+0.02 (0.19%)
| OBAGI MEDICAL PRODS (NASDAQ:OMPI) Delayed : |
| Previous Close |
$10.74 |
|
52 Week High |
$11.80 |
|
| Open |
$10.67 |
|
52 Week Low |
$3.79 |
| Day High |
$11.05 |
|
P/E |
27.59 |
| Day Low |
$10.39 |
|
EPS |
$0.39 |
| Volume |
46,231 |
|
|
|
| More OMPI Info:
Chart
SEC Filings
Profile
Historical
Options
|
View All ReportsStreetInsider.com Reports on OMPI
-
Nov 6, 2009 01:12 PM
Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
-
Nov 5, 2009 05:11 PM
OBAGI Medical (OMPI) Posts Q3 EPS of $0.14, In-Line with Street; Guides
-
Nov 4, 2009 02:42 PM
Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
-
Oct 7, 2009 08:34 AM
Brean Murray Downgrades St. Jude Medical (STJ) to Hold
-
Aug 10, 2009 09:06 AM
Piper Jaffray Downgrades Obagi Medical Products (OMPI) to Neutral; Significant Upside From Current Estimates Limited
View All Reports
StreetInsider Reports on OMPI by Category
-
Nov 19, 2009 08:46 AM
23 Magic Formula Stocks on Forbes' Top 200 Small Companies List
-
Aug 7, 2009 11:40 AM
Analyst upgrades, downgrades and initiations: ACI, CMCSA, DF, HPQ, LEAP, ZLC ...
-
Jul 7, 2009 11:05 AM
Analyst upgrades, downgrades and initiations: BJ, INTC, MMM, MRVL, NSM ...
-
Jun 2, 2009 11:35 AM
Analyst upgrades, downgrades and initiations: CAL, NETL, MAPP, DDUP, LMT ...
-
May 5, 2008 08:01 PM
Obagi Medical Products, Inc. Q1 2008 Earnings Call Transcript
View All Blogs
Comments on recent OMPI articles
Comments on OMPI
No comments are currently available.
on Mar 10, 2009
at 06:48 PM Analysis Good call, not..
Article: Baird Downgrades Obagi Medical Products (OMPI) to Neutral
on May 6, 2008
at 01:55 PM From Wall Street to Wu Street China ("Wu Street") could be the next Wall Street. Investors need to treat such emerging markets like they treated tech start-ups in the '90s, because the odds are much, much better, now.
Article: Pre-Open Movers: Fannie Mae (FNM) Lower on Large Loss/Capital Raise; Innophos (IPHS) Up on Strong Results